Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencing

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8805-8807

  Brumme, Chanson ^a,b   Huber, Kelly D ^c   Dong, Winnie ^a   Poon, Art F Y ^a,b   Harrigan, P Richard ^a,b   Sluis Cremer, Nicolas ^c  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETRAVIRINE; ISOLEUCINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; TYROSINE; VALINE; VIRUS RNA;

454 DEEP SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CODON; GENETIC VARIABILITY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MUTATION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; VIRUS CULTURE; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRULENCE; VIRUS CULTIVATION; VIRUS REPLICATION;

EID: 84880621221     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00335-13     Document Type: Article

References (5)

1. Dykes C, Demeter LM. 2007. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin. Microbiol. Rev.. 20:550-578.
2. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Beáthune MP. 2004.TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitorresistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 48:4680-4686.
3. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B; DUET-2 study group. 2007. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 370:39-48.
4. Vingerhoets J, Tambuyzer L, Azijn H, Hoogstoel A, Nijs S, Peeters M, de Beáthune MP, De Smedt G, Woodfall B, Picchio G. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS. 24:503-514.
5. Shi C, Mellors JW. 1997. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob. Agents Chemother.. 41:2781-2785.